IRF4公司
基诺美
基因敲除
癌症研究
信号转导
多发性骨髓瘤
细胞生长
激酶
基因沉默
细胞生物学
磷酸化
生物
干扰素
下调和上调
细胞
功能(生物学)
小发夹RNA
基因表达调控
细胞培养
化学
IκB激酶
药理学
干扰素调节因子
小干扰RNA
RNA干扰
MAPK/ERK通路
细胞信号
作者
K J Tang,Dongpeng Jiang,Peng Ke,Xiaosen Bian,Lili Zhang,Ying Zhang,Tingting Zhu,Weiwei Qu,Wenhui Qi,Yan Xu,Chengcheng Fu,Depei Wu,Jianhong Chu
标识
DOI:10.1002/advs.202518975
摘要
Multiple myeloma (MM) remains incurable, necessitating development of novel therapeutic targets. Deregulated PRKCN is implicated in solid tumors, while its role in MM remains elusive. Here, PRKCN is identified as a super-enhancer-driven gene associated with adverse prognosis in MM. PRKCN is transactivated by NF-κB signaling intrinsically existing or exogenously provoked. Constitutive or inducible knockdown of PRKCN significantly impairs cell growth and tumorigenicity, while overcoming drug resistance. PRKCN harnesses IRF4 to exert its effect, and in turn, IRF4 directly induces PRKCN transcription, establishing a feed-forward IRF4-PRKCN circuit. Furthermore, PRKCN fosters IRF4 expression by activating mTORC1/C2 signaling pathways via physical interaction with mTOR. Surprisingly, PRKCN modulates mTOR-IRF4 axis and cell growth independently of its acknowledged kinase activity yet requiring activation loop phosphorylation. Intriguingly, PRKCN silencing evokes interferon signaling and confers increased sensitivity to interferon. Finally, targeting PRKCN with an orally bioavailable inhibitor suppresses MM cell growth and overcomes drug resistance in vitro, and elicits robust efficacy in cell line-derived xenografts and a patient-derived xenograft, which is connected with the mitigated PRKCN expression and activation loop phosphorylation as well as blunted mTOR-IRF4 axis. Collectively, our study delineates PRKCN function that links aberrant NF-κB signaling and mTOR-IRF4 axis, supporting clinically targeting PRKCN in MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI